Clinical Trial Update: Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors [Phase 1]

View source ↗

Summary

Phase I study of [225Ac]Ac-ETN029 for DLL3-expressing advanced solid tumors is currently recruiting, sponsored by Novartis Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Carcinoma
• Large Cell Neuroendocrine Carcinoma of the Lung
• Neuroendocrine Prostate Cancer
• Small Cell Lung Cancer

Drugs mentioned

• [225Ac]Ac-ETN029

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Status: RECRUITING